Preferred Label : Capecitabine/Trastuzumab/Tucatinib Regimen;
NCIt synonyms : Capecitabine-Herceptin-Tukysa; Capecitabine/Herceptin/Tukysa; Capecitabine/Trastuzumab/Tucatinib; Capecitabine-Trastuzumab-Tucatinib; Capecitabine-Trastuzumab-Tucatinib Regimen;
NCIt related terms : Capecitabine and Trastuzumab (XH) and Tucatinib; Capecitabine and Trastuzumab-anns (XH) and Tucatinib; Capecitabine and Trastuzumab-zerc (XH) and Tucatinib; Capecitabine and Trastuzumab-qyyp (XH) and Tucatinib; Capecitabine and Trastuzumab-dttb (XH) and Tucatinib; Capecitabine and Trastuzumab-herw (XH) and Tucatinib; Capecitabine and Trastuzumab-pkrb (XH) and Tucatinib; Capecitabine and Trastuzumab-dkst (XH) and Tucatinib;
NCIt definition : A regimen consisting of capecitabine, trastuzumab and tucatinib that can be used in
the treatment of advanced unresectable or metastatic HER2-positive breast cancer.;
NCI Metathesaurus CUI : CL1405489;
Codes from synonyms : 987; 128810; 129101; 129004; 128907; 129295; 129198; 129392;
Origin ID : C171375;
UMLS CUI : C5419112;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3273459/fr/tukysa-tucatinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
tucatinib
antineoplastic agents
protein kinase inhibitors
tucatinib
antineoplastic combined chemotherapy protocols
Trastuzumab
Capecitabine
Capecitabine/Trastuzumab/Tucatinib Regimen
adult
breast neoplasms
HER2-Positive Breast Carcinoma
evaluation of the transparency committee
oxazoles
pyridines
quinazolines
---
